Inscripta成立于2015年,致力于创造革新人类饮食、燃料和疾病治疗方式所需的工具。这些工具包括开发一系列CRISPR酶,为研究人员和商业合作伙伴定制核酸酶,以及一整套基因编辑工具(仪器、试剂和软件),和完全自动化的工作流程,可支持大规模并行的、可跟踪的单细胞编辑。通过这样的工具和方式,可显著提高多重精确基因的编辑速度和效率。
参考资料:
[1] Inscripta Raises $125M in Series D Financing to Accelerate Commercialization of Revolutionary Digital Genome Engineering Platform retrieved December 11 2019 from https://www.businesswire.com/news/home/20191210005110/en/Inscripta-Raises-125M-Series-Financing-Accelerate-Commercialization
[2] $125 million for Inscripta may usher in the next wave of genetic engineering retrieved December 11 2019 from https://techcrunch.com/2019/12/10/125-million-for-inscripta-may-usher-in-the-next-wave-of-genetic-engineering/